{"organizations": [], "uuid": "df1dd19bff1639769f8530821f835e0a64f7ed51", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.ft.com", "main_image": "http://im.ft-static.com/content/images/407cf326-0e85-4bdc-b2bc-b50135f96bac.img", "site_section": "http://www.ft.com/rss/personal-finance", "section_title": "Personal Finance", "url": "http://www.ft.com/cms/s/0/34e35e12-72a0-11e5-bdb1-e6e4767162cc.html?ftcamp=published_links%2Frss%2Fpersonal-finance%2Ffeed%2F%2Fproduct", "country": "US", "title": "Biotech sell-off hurts specialist funds", "performance_score": 0, "site": "ft.com", "participants_count": 0, "title_full": "Biotech sell-off hurts specialist funds", "spam_score": 0.0, "site_type": "news", "published": "2015-10-15T14:13:00.000+03:00", "replies_count": 0, "uuid": "df1dd19bff1639769f8530821f835e0a64f7ed51"}, "author": "", "url": "http://www.ft.com/cms/s/0/34e35e12-72a0-11e5-bdb1-e6e4767162cc.html?ftcamp=published_links%2Frss%2Fpersonal-finance%2Ffeed%2F%2Fproduct", "ord_in_thread": 0, "title": "Biotech sell-off hurts specialist funds", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Read more \n“Given the way that the sector has traded this year, with very strong performance in the first half, the sell-off is perhaps unsurprising. \n“We have, however, been disappointed that stocks such as Prothena and Northwest Biotherapeutics have become so embroiled in it — the valuation attached to their shares is very far from the bubble-like levels that some . . . peers have reached.” \nThe company has seen nothing to change the fundamental investment case for these stocks, he said. \n“Although September was a disappointing month in performance terms, we retain absolute conviction in the long-term outlook for the trust,” Mr Fraser-Jones added. \nPatient Capital, which mainly invests in early-stage and early-growth companies — not exclusively in the biotech sector — is designed for investors who intend to commit their money for at least five years. \nIt has shed 2.2 per cent of net asset value since its launch in April , but is still trading at an 8.8 per cent premium because of investors’ faith in Mr Woodford’s extended record. \nLinden Thomson, manager of the Axa biotech fund , said her fund does not hold Valeant or Turing Pharmaceuticals, two of the companies most associated with drug price inflation, since she does not classify them as biotechnology companies. \nLike Mr Woodford, she has made no significant changes to her portfolio — whose largest holdings are Celgene Corp and Gilead Sciences — as a result of recent market swings. \n“We believe that fundamentals remain solid for this sector and maintain our forecast of 20 per cent growth over the next two years,” said Ms Thomson. \n“In an environment concerned about growth, the biotech sector is one area which looks likely to continue to grow strongly through various market cycles.” \nDemographic trends and demand from countries outside the US and western Europe will continue to support the industry, she added, although it does face question marks over the sustainability of high drug prices, and must negotiate competition from generic drugs. \nRival healthcare funds have also taken a hit: Polar Capital’s biotechnology fund shed 13.4 per cent over the three months to the end of September, while biotech funds run by Candriam Investors Group and Pictet Asset Management were down 14.7 and 13.4 per cent respectively. \nAmong trusts, Frostrow’s Biotech Growth Trust is down 23.5 per cent over three months, and the Worldwide Healthcare Trust , run by the same company, has shed 13.3 per cent of its value.", "external_links": [], "published": "2015-10-15T14:13:00.000+03:00", "crawled": "2015-10-15T18:10:44.527+03:00", "highlightTitle": ""}